Same old news again-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Same old news again

Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Drug Shortage

Shares of Hims & Hers Health Inc. plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.Hims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has be

Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Drug Shortage

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":356111310577776,"tweetId":"356111310577776","gmtCreate":1727950711814,"gmtModify":1727950715713,"author":{"id":4088945193415610,"idStr":"4088945193415610","authorId":4088945193415610,"authorIdStr":"4088945193415610","name":"judyspt","avatar":"https://static.tigerbbs.com/28075c7d730eb01e7fab4597684478f4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.22","exceedPercentage":"93.79%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Same old news again&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Same old news again&nbsp;</p></body></html>","text":"Same old news again","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/356111310577776","repostId":1135720096,"repostType":2,"repost":{"id":"1135720096","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1727942673,"share":"https://www.laohu8.com/m/news/1135720096?lang=&edition=full","pubTime":"2024-10-03 16:04","market":"hk","language":"en","title":"Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Drug Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=1135720096","media":"Stock Track","summary":"Shares of Hims & Hers Health Inc.  plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.Hims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has be","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.</p>\n\n<p>Hims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has been able to do so due to federal laws that allow compounding pharmacies to produce copies of drugs that are in shortage.</p>\n\n<p>However, the Food and Drug Administration (FDA) is currently working to determine whether the supply of these drugs is sufficient to consider the shortages resolved. If the FDA lifts the shortage designation, compounding pharmacies would be required to stop producing the copycat drugs within 60 days, potentially dealing a significant blow to Hims & Hers' revenue from this segment.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Drug Shortage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Drug Shortage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-03 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.</p>\n\n<p>Hims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has been able to do so due to federal laws that allow compounding pharmacies to produce copies of drugs that are in shortage.</p>\n\n<p>However, the Food and Drug Administration (FDA) is currently working to determine whether the supply of these drugs is sufficient to consider the shortages resolved. If the FDA lifts the shortage designation, compounding pharmacies would be required to stop producing the copycat drugs within 60 days, potentially dealing a significant blow to Hims & Hers' revenue from this segment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135720096","content_text":"Shares of Hims & Hers Health Inc. (HIMS) plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.\nHims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has been able to do so due to federal laws that allow compounding pharmacies to produce copies of drugs that are in shortage.\nHowever, the Food and Drug Administration (FDA) is currently working to determine whether the supply of these drugs is sufficient to consider the shortages resolved. If the FDA lifts the shortage designation, compounding pharmacies would be required to stop producing the copycat drugs within 60 days, potentially dealing a significant blow to Hims & Hers' revenue from this segment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}